5[6]Felson DT,Anderson JJ,Boers M,et al.American College of Rheumatology.Preliminary definition of improvement in rheumatoid arthritis.Arthritis Rheum,1995,38 (6):727-735
6[7]Smolen JS,Kalden JR,Scott DL,et al.Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind,randomised,multicentre trial.European Leflunomide Study Group.Lancet,1999,353(9149):259-266
7[8]Strand V,Cohen S,Schiff M,et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.Leflunomide Rheumatoid Arthritis Investigators Group.Arch Intern Med,1999,159 (21):2542-2550
8[9]Cohen S,Cannon GW,Schiff M,et al.Two-year,blinded,randomized,controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate.Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.Arthritis Rheum,2001,44 (9):1984-1992
9[10]Lee H,Kimko HC,Rogge M.Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.Clin Pharmacol Ther,2003,73 (4):348-365
10[11]Bathon JM,Martin RW,Fleischmann RM,et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med,2000,343 (22):1586-1593
2Zhang J,Markovic-Plese S,Lacet B, et al. Increased frequmcy of interleukin 2-resgonsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med, 1994,179: 973-984.
3Simon AK,Seipelt E,Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA, 1994, 91: 8562-8566.
4Beraud E , Balzano C , Zamora AJ , et al . Pathogenic and non -pathogenic T lymphocytcs specific for the encephalitogenic epitope of myelin basic protein: functional characteristics and vaccination propertics. J Neuroimmunol, 1993,47: 41-53.
5Peterson KE,Braley-Mullen H. Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyrogldmlin. Cell Immunol, 1995,166:123-130.
6Malfait AM,Williams RO, Malik AS,et al. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum,2001,44:1215-1224.
7Larsson P,Kleinau S,Holmdahl R,et al.Homologous type Ⅱ collagen-induced arthritis in rats: characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum, 1990,33: 693-701.
8Lafyatis R., Remmers E. F., Roberts A. B., et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J. Clin. Invest. ,1989; 83(4):1267-1276.
9Muller-Ladner U. , Kriegsmann J. , Franklin B. N. , et al.Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol., 1996; 149(5): 1607-1615.
10Kuenzler P., Kuchen S., Rihoskova V., et al. Induction of p16 at sites of cartilage invasion in the SCID mouse coimplantation model of rheumatoid arthritis. Arthritis Rheum, 2003;48(7) : 2069-2073.
